CAR T cells for solid tumors – developments to watch in 2023

Click to increase image sizeClick to decrease image size

Declaration of interests

S Kobold has received honoraria from TCR2 Inc., Miltenyi, Galapagos, Novartis, BMS, and GSK. S Kobold is an inventor of several patents in the field of immuno-oncology. S Kobold received license fees from TCR2 Inc and Carina Biotech. S Kobold received research support from TCR2 Inc., Tabby Therapeutics, Catalym GmBH, Plectonic GmBH and Arcus Bioscience for work unrelated to the manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

A reviewer on this manuscript has disclosed that they are a member of the senior leadership team at Leucid Bio, a CAR T-cell company focused on solid tumor immunotherapy. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was funded by the Swiss National Science Foundation (SNSF Postdoc. Mobility grant to MP Trefny) and the Monika-Kutzner Stiftung (to MP Trefny). This work was supported by the Bavarian Cancer Research Center (BZKF) (TANGO to S Kobold), the Deutsche Forschungsgemeinschaft (DFG, grant number: KO5055-2-1 and KO5055/3-1 to S Kobold), the international doctoral program ‘i-Target: immunotargeting of cancer’ (funded by the Elite Network of Bavaria; to S Kobold), the Melanoma Research Alliance (grant number 409510 to S Kobold), Marie Sklodowska-Curie Training Network for Optimizing Adoptive T Cell Therapy of Cancer (funded by the Horizon 2020 programme of the European Union; grant 955575 to S Kobold), Else Krner-Fresenius-Stiftung (IOLIN to S Kobold), German Cancer Aid (AvantCAR.de to S Kobold), the Wilhelm-Sander-Stiftung (to S Kobold), Ernst Jung Stiftung (to S Kobold), Institutional Strategy LMUexcellent of LMU Munich (within the framework of the German Excellence Initiative; to S Kobold), the Go-Bio-Initiative (to S Kobold), the m4-Award of the Bavarian Ministry for Economic Affairs (to S Kobold), Bundesministerium für Bildung und Forschung (to S Kobold), European Research Council (Starting Grant 756017, PoC Grant 101100460 and CoG 101124203 to S Kobold), by the SFB-TRR 338/1 2021–452881907 (to S Kobold), Fritz-Bender Foundation (to S Kobold), Deutsche José Carreras Leukämie Stiftung (to S Kobold), Hector Foundation (to S Kobold), Bavarian Research Foundation (BAYCELLATOR to S Kobold), the Bruno and Helene Jöster Foundation (360° CAR to S Kobold).